GILD

ACCE-researched
Gilead Sciences Inc. Common Stock
Healthcare · Drug Manufacturers - General · NASDAQ · United States
$150.56+0.30%
Market cap $186.1BNext earnings 2026-10-29Updated Sep 19, 2026
FAIR VALUE · CONSENSUS
$150.56+0.0%
confidence-weighted across 3 of 6 models
Now $150.56
$150.56
$52.72$120.15
AvoidSilver63
Price vs fair value
58.4% above
-36.9% to fair value
ACCE score
64
out of 100
Analysts
63% buy
30 covering
P/E
0.0x
forward 15.3x
1-year return
+32.0%
Dividend yield
2.13%
Unlock the ACCE read
INVESTOR

Overview

⚠ Investor warnings · 3 flags
  • moderate
    Sequential revenue deceleration
    QoQ revenue growth of -12.2% contrasts sharply with +4.4% YoY, signaling a meaningful near-term slowdown worth monitoring.
  • moderate
    Insider selling, no buying
    $6.04M in insider sales with $0 in buys over last 10 disclosed transactions suggests limited insider conviction at current levels.
  • moderate
    Elevated leverage
    Debt/Equity of 1.10 is meaningful for a pharma company, though $9.5B FCF provides adequate coverage.
Reports in 36 days, last quarter beat by 0.0%.

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Price

+33.8% · 1Y

Valuation

INVESTOR
Full valuation engine INVESTOR FEATURE

Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.

  • +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
  • +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
  • +Editable DCF workbench with saved scenarios

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.

  • +Conviction score breakdown and earnings-quality grade
  • +Growth / value / quality / momentum component scores
  • +90-day score history and score-threshold backtests

Analysts

Wall Street consensus

Bullish63% buy · 30 covering analysts
● Strong buy 15● Buy 4● Hold 11● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO
Smart money tracking PRO FEATURE

Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Recent open-market insider transactions
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

This stock Peer Peer median weaker → stronger
P/Ebetter than 100% of peers
low 0.0x0.0xhigh 36.4x
ROEbetter than 0% of peers
low -21%-21%high 91%
Div yieldbetter than 17% of peers
low 1.9%2.1%high 6.2%

Algorithmic peers (6)

TickerCompanyMcapP/EROED/EYieldQuality
NVONovo Nordisk A/S Common Stock$191.0B10.759.8%0.674.2%-Compare
NOVO-B.CONovo Nordisk B$191.2B10.759.8%0.634.2%-Compare
AMGNAmgen Inc. Common Stock$208.5B24.091.5%6.312.6%-Compare
PFEPfizer Inc. Common Stock$157.7B36.45.0%0.746.2%-Compare
AZNAstraZeneca PLC Ordinary Shares$257.6B24.922.0%0.571.9%-Compare
AZN.LAstraZeneca$260.9B25.122.0%0.572.6%-Compare

Sector report card

Where GILD ranks against its sector peers on each metric.

Computing percentiles…

News and Record

Reports in 36 days, last quarter beat by 0.0%.

Press releases mentioning this company

Ask anything, Pro feature

Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.

PRO

Recent performance

1 week
+2.8%
1 month
+3.0%
3 months
+20.4%
6 months
+8.9%
YTD
+22.7%
1 year
+32.0%

SEC filings

40 filings
September 2026
Sep 16
Form 4Insider transactionPeriod 2026-09-15
Sep 16
Form 4Insider transactionPeriod 2026-09-15
Sep 11
Form 4Insider transactionPeriod 2026-09-10
37 more filings + AI summaries on Investor+.INVESTOR